- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Revascularization
- Procedure
- Lead sponsor
- Diabetes and Glandular Disease Clinic
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 681
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
- Interventions
- Peripheral balloon angioplasty
- Device
- Lead sponsor
- Cagent Vascular LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Hartford, Connecticut + 15 more
- Conditions
- Coronary Artery Disease, Hypertension, Hyperlipidemias, Peripheral Vascular Diseases, Cerebral Arterial Diseases
- Interventions
- Goodbelly, Placebo
- Dietary Supplement
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Wauwatosa, Wisconsin
- Conditions
- Peripheral Artery Disease
- Interventions
- PAD education video
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Peripheral Arterial Disease
- Interventions
- Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
- Drug · Other
- Lead sponsor
- Leonardo Clavijo
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Peripheral Vascular Disease
- Interventions
- Complete SE Iliac Stent
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Flint, Michigan • New York, New York
- Conditions
- Chronic Limb-Threatening Ischemia
- Interventions
- Esprit BTK System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 36
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Fresno, California + 27 more
- Conditions
- Raynaud's Disease
- Interventions
- Topical organogel with nitroglycerin
- Drug
- Lead sponsor
- MediQuest Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 17
- States / cities
- Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
- Conditions
- Arterial Occlusive Diseases
- Interventions
- Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Peripheral Arterial Disease
- Interventions
- Carnosine
- Biological
- Lead sponsor
- Shahid Baba
- Other
- Eligibility
- 50 Years to 80 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease
- Interventions
- Radial artery mechanical compression for hemostasis
- Device
- Lead sponsor
- Forge Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Missoula, Montana
- Conditions
- Scleroderma, Raynaud's Syndrome
- Interventions
- Onabotulinumtoxin A, sterile saline solution
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Peripheral Artery Disease (PAD)
- Interventions
- GM-CSF, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Peripheral Arterial Disease, Walking, Difficulty, Inflammation
- Interventions
- Calf Plantar flexion, Dietary nitrate
- Device · Dietary Supplement
- Lead sponsor
- University of Wisconsin, La Crosse
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- La Crosse, Wisconsin
- Conditions
- Obstructive Coronary Artery Disease, Obstructive Peripheral Artery Disease, Structural Heart Disease
- Interventions
- Percutaneous Transluminal Angioplasty
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Peripheral Artery Disease
- Interventions
- Tack Endovascular System
- Device
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 36
- States / cities
- Yuma, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
- Interventions
- Nitroglycerin, Topical AmphiMatrix
- Drug
- Lead sponsor
- MediQuest Therapeutics
- Industry
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
- Conditions
- Transtibial Amputation, Peripheral Artery Disease, Diabetes Mellitus
- Interventions
- Error-augmentation gait training, Error-correction gait training, Supervised walking
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 89 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Richmond, Virginia
- Conditions
- Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis
- Interventions
- Dalteparin sodium injection
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Cardiovascular Diseases
- Interventions
- MRI
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Critical Limb Ischemia, Chronic Limb-Threatening Ischemia
- Interventions
- LimFlow System
- Device
- Lead sponsor
- LimFlow, Inc.
- Industry
- Eligibility
- 21 Years to 95 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Honolulu, Hawaii • Wyoming, Michigan + 4 more
- Conditions
- Peripheral Arterial Disease (PAD) in Cancer Patients
- Interventions
- ABI/TBI, Questionnaires
- Diagnostic Test · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Peripheral Arterial Disease, Critical Limb Ischemia
- Interventions
- Serranator, POBA
- Device
- Lead sponsor
- Cagent Vascular LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Alprostadil, Placebo
- Drug · Other
- Lead sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more